Eric Coldwell
Stock Analyst at Robert W. Baird
(4.54)
# 997
Out of 4,556 analysts
783
Total ratings
57.9%
Success rate
7.3%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintained: Hold | $229 → $236 | $209.83 | +12.47% | 60 | Jul 13, 2026 | |
| MEDP Medpace Holdings | Downgraded: Hold | $477 → $547 | $528.12 | +3.57% | 59 | Jul 8, 2026 | |
| AHCO AdaptHealth | Maintained: Buy | $18 → $15 | $10.88 | +37.87% | 41 | Jul 6, 2026 | |
| IQV IQVIA Holdings | Maintained: Buy | $258 → $249 | $198.52 | +25.43% | 67 | Jul 1, 2026 | |
| ICLR ICON Public Limited Company | Maintained: Buy | $168 → $186 | $167.28 | +11.19% | 70 | Jun 25, 2026 | |
| MDLN Medline | Maintained: Buy | $56 → $45 | $37.18 | +21.03% | 3 | Jun 2, 2026 | |
| ACH Accendra Health | Maintained: Buy | $7 → $6 | $3.16 | +89.87% | 72 | May 12, 2026 | |
| CRL Charles River Laboratories International | Maintained: Buy | $193 → $213 | $218.70 | -2.61% | 70 | May 8, 2026 | |
| MCK McKesson | Maintained: Buy | $974 → $941 | $814.04 | +15.60% | 77 | May 8, 2026 | |
| COR Cencora | Maintained: Buy | $415 → $339 | $300.58 | +12.78% | 74 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $20 | $18.49 | +8.17% | 14 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $252 → $248 | $220.54 | +12.45% | 69 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $326 → $334 | $281.46 | +18.67% | 73 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $110 | $108.08 | n/a | 28 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $23 → $22 | $4.80 | n/a | 6 | May 9, 2014 |
Quest Diagnostics
Jul 13, 2026
Maintained: Hold
Price Target: $229 → $236
Current: $209.83
Upside: +12.47%
Medpace Holdings
Jul 8, 2026
Downgraded: Hold
Price Target: $477 → $547
Current: $528.12
Upside: +3.57%
AdaptHealth
Jul 6, 2026
Maintained: Buy
Price Target: $18 → $15
Current: $10.88
Upside: +37.87%
IQVIA Holdings
Jul 1, 2026
Maintained: Buy
Price Target: $258 → $249
Current: $198.52
Upside: +25.43%
ICON Public Limited Company
Jun 25, 2026
Maintained: Buy
Price Target: $168 → $186
Current: $167.28
Upside: +11.19%
Medline
Jun 2, 2026
Maintained: Buy
Price Target: $56 → $45
Current: $37.18
Upside: +21.03%
Accendra Health
May 12, 2026
Maintained: Buy
Price Target: $7 → $6
Current: $3.16
Upside: +89.87%
Charles River Laboratories International
May 8, 2026
Maintained: Buy
Price Target: $193 → $213
Current: $218.70
Upside: -2.61%
McKesson
May 8, 2026
Maintained: Buy
Price Target: $974 → $941
Current: $814.04
Upside: +15.60%
Cencora
May 7, 2026
Maintained: Buy
Price Target: $415 → $339
Current: $300.58
Upside: +12.78%
May 6, 2026
Maintained: Buy
Price Target: $16 → $20
Current: $18.49
Upside: +8.17%
May 1, 2026
Maintained: Buy
Price Target: $252 → $248
Current: $220.54
Upside: +12.45%
May 1, 2026
Maintained: Buy
Price Target: $326 → $334
Current: $281.46
Upside: +18.67%
Apr 18, 2022
Maintained: Hold
Price Target: $110
Current: $108.08
Upside: n/a
May 9, 2014
Rated: Buy
Price Target: $23 → $22
Current: $4.80
Upside: n/a